These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36053490)

  • 21. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
    Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
    Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relationship between Polymorphism of miR-155 and Its Target Gene MyD88 and Clinicopathological Features of Diffuse Large B-cell Lymphoma].
    Li Y; Jia ZW; Kong XY; Cui GR; Liu XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):757-762. PubMed ID: 34105469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [CD5- and CD10-positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88
    Sasaki Y; Murai S; Okamura R; Uesugi Y; Shimada S; Watanuki M; Fujiwara S; Kawaguchi Y; Arai N; Yanagisawa K; Honma M; Yamochi T; Hattori N
    Rinsho Ketsueki; 2023; 64(1):42-48. PubMed ID: 36775306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
    Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
    World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
    Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
    Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
    Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
    BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.
    Tang D; Su W; Wang X; Chu Z; Zhang L; Zhou J; Zhang Q
    Brain Tumor Pathol; 2021 Jan; 38(1):50-58. PubMed ID: 33079297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
    Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
    Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
    Lee YS; Liu J; Fricano KA; Webb EM; Toolsie DR; Jones S; Rhoads JA; Vij R; Cashen AF; Abboud CN; Westervelt P; Bartlett NL; Dipersio JF; Kreisel FH; Lim KH
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2199-2204. PubMed ID: 28847710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
    Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
    BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
    Caner V; Sen Turk N; Baris IC; Cetin GO; Tepeli E; Hacioglu S; Sari I; Zencir S; Dogu MH; Bagci G; Keskin A
    Genet Test Mol Biomarkers; 2015 Jul; 19(7):372-8. PubMed ID: 25978699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
    Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.
    Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
    Shekhar R; Naseem S; Binota J; Varma N; Malhotra P
    Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
    Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
    Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.
    Shi H; Zhou X; Chen B; Xiao J; Li Y; Zhou X; Zhou Q; Chen K; Wang Q
    Ocul Immunol Inflamm; 2021 Apr; 29(3):448-455. PubMed ID: 31603365
    [No Abstract]   [Full Text] [Related]  

  • 40.
    Vermaat JS; Somers SF; de Wreede LC; Kraan W; de Groen RAL; Schrader AMR; Kerver ED; Scheepstra CG; Berenschot H; Deenik W; Wegman J; Broers R; de Boer JD; Nijland M; van Wezel T; Veelken H; Spaargaren M; Cleven AH; Kersten MJ; Pals ST
    Haematologica; 2020; 105(2):424-434. PubMed ID: 31123031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.